Wilson analyst report sums it up well indicating the efti+Keytruda should be first choice
"This OS data suggests clinicians many no longer need to weigh up incremental survival benefit with add-on chemo, and associated side effect burden, with the Efti combination able to deliver on OS (matching/bettering chemo) with a superior tolerability profile.
This is compelling and we expect IMM to be a hot topic of discussion at ASCOin a few weeks’ time (June 2-6th), having demonstrated such impressive OS data in the absenceof chemotherapy."
(Benson, Storey, & Williams, 2023)
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC, page-12
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $459.4K | 1.254M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63364 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 133642 | 8 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |